The end of the blockbuster?
A new report from Datamonitor predicts the end of the
pharmaceutical industry's blockbuster product model, pointing to a
dramatic shortfall in growth rates for billion dollar-plus products
out to 2008.
Xenova plans to buy KS Bio
Xenova has become the latest company to ride the wave of
consolidation sweeping the UK biotechnology industry by offering to
buy KS Biomedix.
Bayer's Walothen subsidiary sold off
German chemicals and drugs company Bayer has said that it plans to
sell its subsidiary Walothen to Finland's Wihuri as part of an
ongoing restructuring of its portfolio.
Daicel forges US links to expand business
Daicel has entered into an agreement with Thesis Chemistry in a
deal which will see the two companies collaborate in the area of
chiral process manufacturing.
Degussa sees sales, profits slump in second quarter
Degussa follows its peers in the speciality chemicals industry by
posting weak interim results held back by currency factors, raw
material costs and lower demand.
China Pharma triples net profit
China Pharma sees revenues and net profits soar in first half, but
analysts say bulk drugs may come under pricing pressure going
Swedish biotechs link up
Pyrosequencing, a genetic analysis systems manufacturer, has
acquired a 94.1 per cent stake in chemical synthesis concern
Personal Chemistry in an all-stock transaction.
FTC takes on alleged process control software monopoly
The US FTC has taken issue with the merger between Aspen Technology
and Hyprotech in 2002, alleging that it gave the combined firm a
too-dominant position in process control software.
BASF sees no recovery until fourth quarter
BASF, the world's largest chemicals company, has said that it will
expand an ongoing restructuring program in North America after
reporting lower-than-expected second-quarter sales and profits.
Caliper sheds jobs after Zymark buy
Caliper has cut 9 per cent of its staff as part of a restructuring
exercise following its $72 million acquisition of lab automation
Bayer sales on the slide in second quarter
Bayer has reported a decline in net profits for the second quarter
of 2003, with analysts expressing concerns that litigations costs
could hold back full-year earnings.
Cambrex sells non-core business
Cambrex plans to sell off its Rutherford Chemicals business for $64
million (€56m) to allow it to focus on its human health and
New contract manufacturer buys plant
KBI BioPharma, a start-up biopharma contract manufacturer, has
signed an agreement to buy a facility in North Carolina that could
be online in 6-9 months.
Cobra signs cancer vaccine production deal
Cobra Biomanufacturing has signed an agreement to supply Advaxis
with clinical and commercial supplies of its Listeria
monocytogenes-based cancer vaccine.
Irish meeting on manufacturing excellence
A conference on batch process automation and asset management in
the pharmaceutical industry is scheduled to take place in Cork,
Ireland, on 22-23 October.